DeepMed Research

Cladribine

Generic Name: Cladribine

Brand Names: Litak, Mavenclad

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂ClN_₅O_₃

CAS Number: 4291-63-8

Unique Ingredient Identifier: 47M74X9YT5

Background: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.

Indication: For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.

Associated Conditions: Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)

Clinical Trials

Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment

Phase 1

Not yet recruiting

Conditions: Hairy Cell Leukemia
Recurrent Hairy Cell Leukemia
Refractory Hairy Cell Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cladribine
Biological: Rituximab
Drug: Tovorafenib

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT06965114

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Phase 4

Not yet recruiting

Conditions: Relapsed/Refractory AML

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: G-CSF
Drug: Venetoclax

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 172

Registration Number: NCT06763666

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Cladribine Tablets as an Exit Therapy Strategy

Not yet recruiting

Conditions: Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis

Interventions: Drug: Cladribine

First Posted Date: 2025-03-20

Last Posted Date: 2025-03-20

Lead Sponsor: University Hospital, Strasbourg, France

Target Recruit Count: 450

Registration Number: NCT06887426

Locations: 🇫🇷
Service de neurologie - Hôpitaux Universitaires de Strasbourg, Strasbourg, France

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Cell Leukemia (HCL)

Phase 2

Recruiting

Conditions: Hairy Cell Leukemia

Interventions: Drug: Vemurafenib
Drug: Cladribine
Drug: Obinutuzumab
Drug: Rituximab

First Posted Date: 2024-08-20

Last Posted Date: 2024-10-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 86

Registration Number: NCT06561360

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 7 locations

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Phase 1

Recruiting

Conditions: Refractory Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia

Interventions: Drug: Tagraxofusp
Drug: Cladribine (CLAD)
Drug: Cytarabine

First Posted Date: 2024-08-19

Last Posted Date: 2025-03-17

Lead Sponsor: Stanford University

Target Recruit Count: 20

Registration Number: NCT06561152

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Venetoclax in Combination with Cladribine and Cytarabine Alternating with Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia
Acute Monocytic Leukemia

Interventions: Drug: Azacitidine
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cladribine
Drug: Cytarabine
Procedure: Echocardiography
Procedure: Lumbar Puncture
Procedure: Multigated Acquisition Scan
Other: Questionnaire Administration
Drug: Venetoclax

First Posted Date: 2024-07-16

Last Posted Date: 2025-03-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 40

Registration Number: NCT06504459

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

Phase 1

Not yet recruiting

Conditions: Refractory Acute Leukemia
Relapsed Acute Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Sorafenib
Drug: Decitabine

First Posted Date: 2024-06-26

Last Posted Date: 2025-02-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT06474663

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Cladribine Low Dose
Other: Placebo
Drug: Cladribine High Dose

First Posted Date: 2024-06-18

Last Posted Date: 2025-05-07

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 240

Registration Number: NCT06463587

Locations: 🇺🇸
The University of Vermont Medical Center, Burlington, Vermont, United States
🇯🇵
Osaka University Hospital - Dept of Neurology/Stroke Care Unit, Suita-shi, Japan
🇵🇱
Wielospecjalistyczne Centrum Medyczne Ibismed - Dept of Neurology, Zabrze, Poland

and more 32 locations

Cladribine Venetoclax in Monocytic AML

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2024-01-31

Last Posted Date: 2025-01-03

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 40

Registration Number: NCT06232655

Locations: 🇺🇸
Universtiy of Colorado Hospital, Aurora, Colorado, United States

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Phase 1

Active, not recruiting

Conditions: Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Cladribine

First Posted Date: 2023-09-01

Last Posted Date: 2025-03-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06021600

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy